Childhood acute and chronic immune-mediated polyradiculoneuropathies

European Journal of Paediatric Neurology

Volumn 13, Issue 3, 2009, Pages 209-218

  Rabie, Malcolm ^a   Nevo, Yoram ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Childhood acquired polyneuropathy; CIDP; Guillain Barr

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; B LYMPHOCYTE ANTIGEN; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DEXAMETHASONE; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; SODIUM CHANNEL BLOCKING AGENT; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ASTHENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; CEREBROSPINAL FLUID ANALYSIS; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; DEMYELINATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; EDEMA; ELECTROLYTE DISTURBANCE; EVIDENCE BASED MEDICINE; EYE DISEASE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GUILLAIN BARRE SYNDROME; HEMATOLOGIC DISEASE; HIRSUTISM; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; INFECTION; LEUKOPENIA; LIVER DISEASE; LIVER FUNCTION; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEOPLASM; NEPHROTOXICITY; NERVE FIBER; NEUROPATHY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RASH; RELAPSE; REVIEW; SIDE EFFECT; THYROID DISEASE; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING;

ACUTE DISEASE; CHILD; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; POLYRADICULONEUROPATHY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; STEROIDS;

EID: 64449086272     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2008.04.009     Document Type: Review

References (94)

1. Kieseier B.C., Kiefer R., Gold R., et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30 (2004) 131-156
2. Hughes R.A., Swan A.V., and van Doorn P.A. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 4 (2004) CD003280
3. Hadden R.D.M., and Hughes R.A.C. Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatr 74 Suppl. (2003) ii9-ii14
4. van Doorn P.A. Treatment of Guillain-Barré syndrome and CIDP. J Peripher Nerv Syst 10 (2005) 113-127
5. Hughes R.A., Swan A.V., Raphaël J.C., et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130 (2007) 2245-2257
6. Rabie M., Sander H.W., and Nevo Y. Acute and chronic immune-mediated polyneuropathy. In: Burg F.D., Ingelfinger J.R., Polin R.A., and Gershon A.A. (Eds). Current pediatric therapy. 18th ed. (2006), Saunders Elsevier, Philadelphia 364-367
7. Asbury A.K. New concepts of Guillain-Barré syndrome. J Child Neurol 15 (2000) 183-191
8. Willison H.J., and Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125 (2002) 2591-2625
9. Asbury A.K., and Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27 Suppl. (1990) S21-S24
10. Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41 (1991) 617-618
11. Hughes R.A., Bouche P., Cornblath D.R., et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 13 (2006) 326-332
12. Sander H.W., and Hedley-Whyte E.T. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2003. A nine-year-old girl with progressive weakness and areflexia. N Engl J Med 348 (2003) 735-743
13. Nevo Y., and Topaloglu H. 88th ENMC international workshop: childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria), Naarden, The Netherlands, December 8-10, 2000. Neuromuscul Disord 12 (2002) 195-200
14. Griffin J.W., Li C.Y., Ho T.W., et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 39 (1996) 17-28
15. McKhann G.M., Cornblath D.R., Griffin J.W., et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33 (1993) 333-342
16. Nagasawa K., Kuwabara S., and Misawa S. Electrophysiological subtypes and prognosis of childhood Guillain-Barré syndrome in Japan. Muscle Nerve 33 (2006) 766-770
17. Hughes R.A.C., and Cornblath D.R. Guillain-Barré syndrome. Lancet 366 (2005) 1653-1666
18. Tekgul H., Serdaroglu G., and Tutuncuoglu S. Outcome of axonal and demyelinating forms of Guillain-Barré syndrome in children. Pediatr Neurol 28 (2003) 295-299
19. Sladky J.T. Guillain-Barré syndrome in children. J Child Neurol 19 (2004) 191-200
20. Hung P.L., Chang W.N., and Huang L.T. A clinical and electrophysiologic survey of childhood Guillain-Barré syndrome. Pediatr Neurol 30 (2004) 86-91
21. Paradiso G., Tripoli J., Galicchio S., and Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal. Ann Neurol 46 (1999) 701-707
22. Rantala H., Uhari M., and Niemelä M. Occurrence, clinical manifestations, and prognosis of Guillain-Barré syndrome. Arch Dis Child 66 (1991) 706-709
23. Gorson K.C., Ropper A.H., Muriello M.A., and Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology 47 (1996) 813-817
24. Nachamkin I., Barbosa P.A., Ung H., et al. Patterns of Guillain-Barre syndrome in children. Results from a Mexican population. Neurology 69 (2007) 1665-1671
25. Korinthenberg R., and Mönting J.S. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. Arch Dis Child 74 (1996) 281-287
26. Korinthenberg R., Schessl J., and Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 38 (2007) 10-17
27. Hughes R.A., Wijdicks E.F., Barohn R., et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 736-740
28. Gürses N., Uysal S., Cetinkaya F., Işlek I., and Kalayci A.G. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Scand J Infect Dis 27 (1995) 241-243
29. Wang R., Feng A., Sun W., and Wen Z. Intravenous immunoglobulin in children with Guillain-Barré syndrome. [from ref 5]. J Appl Clin Pediatr 16 (2001) 223-224
30. Korinthenberg R., Schessl J., Kirschner J., and Mönting J.S. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 116 (2005) 8-14
31. Hiraga A., Kuwabara S., Ogawara K., et al. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome. Neurology 64 (2005) 856-860
32. Buompadre M.C., Gáñez L.A., Miranda M., and Arroyo H.A. Unusual variants of Guillain-Barré syndrome in infancy. [Abstract]. Rev Neurol 42 (2006) 85-90
33. Lewis R.A. Chronic inflammatory demyelinating polyneuropathy. Neurol Clin 25 (2007) 71-87
34. Hughes R., Sanders E., Hall S., et al. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 49 (1992) 612-616
35. Oh S.J., Kurokawa K., de Almeida D.F., Ryan Jr. H.F., and Claussen G.C. Subacute inflammatory demyelinating polyneuropathy. Neurology 61 (2003) 1507-1512
36. Rodriguez-Casero M.V., Shield L.K., and Kornberg A.J. Subacute inflammatory demyelinating polyneuropathy in children. Neurology 64 (2005) 1786-1788
37. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. J Am Med Assoc 291 (2004) 2367-2375
38. Yuki N., and Kuwabara S. Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst 12 (2007) 238-249
39. Hafer-Macko C.E., Sheikh K.A., Li C.Y., et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39 (1996) 625-635
40. Hadden R.D., Karch H., Hartung H.P., et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Neurology 56 (2001) 758-765
41. Wollinsky K.H., Hülser P.J., Brinkmeier H., et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 57 (2001) 774-780
42. Schessl J., Koga M., Funakoshi K., et al. Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome. Arch Dis Child 92 (2007) 48-52
43. Nevo Y., and Pestronk A. Acute immune polyneuropathies: correlations of serum antibodies to Campylobacter jejuni and Helicobacter pylori with anti-GM1 antibodies and clinical patterns of disease. J Infect Dis 176 Suppl. (1997) S154-S156
44. Goddard E.A., Lastovica A.J., and Argent A.C. Campylobacter 0:41 isolation in Guillain-Barré syndrome. Arch Dis Child 76 (1997) 526-528
45. Nevo Y. Childhood chronic inflammatory demyelinating polyneuropathy. Europ J Paediatr Neurol 2 (1998) 169-177
46. Allen D., Giannopoulos K., Gray I., et al. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 10 (2005) 174-180
47. McKhann G.M., Cornblath D.R., Ho T., et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 338 (1991) 593-597
48. Bradshaw D.Y., and Jones Jr. H.R. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve 15 (1992) 500-506
49. Ryan M.M. Guillain-Barré syndrome in childhood. J Paediatr Child Health 41 (2005) 237-241
50. Bradshaw D.Y., and Jones H.R. Pseudomeningoencephalitic presentation of pediatric Guillain-Barré syndrome. J Child Neurol 16 (2001) 505-508
51. Schessl J., Luther B., Kirschner J., Mauff G., and Korinthenberg R. Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study. Eur J Pediatr 165 (2006) 605-612
52. Takahashi M., Koga M., Yokoyama K., and Yuki N. Epidemiology of Campylobacter jejuni isolated from patients with Guillain-Barré and Fisher syndromes in Japan. J Clin Microbiol 43 (2005) 335-339
53. Caporale C.M., Papola F., Fioroni M.A., et al. Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol 177 (2006) 112-118
54. Coşkun A., Kumandaş S., Paç A., et al. Childhood Guillain-Barré syndrome. MR imaging in diagnosis and follow-up. Acta Radiol 44 (2003) 230-235
55. Hughes R.A., Wijdicks E.F., Benson E., et al. Supportive care for patients with Guillain-Barre syndrome. Multidisciplinary Consensus Group. Arch Neurol 62 (2005) 1194-1198
56. Rantala H., Uhari M., Cherry J.D., and Shields W.D. Risk factors of respiratory failure in children with Guillain-Barré syndrome. Pediatr Neurol 13 (1995) 289-292
57. Wiffen P.J., McQuay H.J., Edwards J.E., and Moore R.A. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 3 (2005) CD005452
58. van der Meché F.G., and Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 326 (1992) 1123-1129
59. Nishimoto Y., Koga M., Kamijo M., Hirata K., and Yuki N. Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology 62 (2004) 1939-1944
60. Epstein M.A., and Sladky J.T. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 28 (1990) 65-69
61. Lamont P.J., Johnston H.M., and Berdoukas V.A. Plasmapheresis in children with Guillain-Barré syndrome. Neurology 41 (1991) 1928-1931
62. Khatri B.O., Flamini J.R., Baruah J.K., Dobyns W.B., and Konkol R.J. Plasmapheresis with acute inflammatory polyneuropathy. Pediatr Neurol 6 (1990) 17-29
63. Jansen P.W., Perkin R.M., and Ashwal S. Guillain-Barré syndrome in childhood: natural course and efficacy of plasmapheresis. Pediatr Neurol 9 (1993) 16-20
64. Koul R., Chacko A., Ahmed R., et al. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras. J Child Neurol 18 (2003) 767-771
65. DiMario Jr. F.J. Intravenous immunoglobulin in the treatment of childhood Guillain-Barré Syndrome: a randomized trial. Pediatrics 116 (2005) 226-228
66. Baranwal A.K., and Parmar V.R. Exchange transfusion as an alternative therapy for recurrent severe Guillain-Barre syndrome. Indian J Pediatr 74 (2007) 689-691
67. Vajsar J., Fehlings D., and Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr 142 (2003) 305-309
68. Ammache Z., Afifi A.K., Brown C.K., and Kimura J. Childhood Guillain-Barré syndrome: clinical and electrophysiologic features predictive of outcome. J Child Neurol 16 (2001) 477-483
69. Ortiz-Corredor F., Peña-Preciado M., and Díaz-Ruíz J. Motor recovery after Guillain-Barré syndrome in childhood. Disabil Rehabil 29 (2007) 883-889
70. Nevo Y., Pestronk A., Kornberg A.J., et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 47 (1996) 98-102
71. Rodriguez-Casero M.V., Shield L.K., Coleman L.T., and Kornberg A.J. Childhood chronic inflammatory demyelinating polyneuropathy with central nervous system demyelination resembling multiple sclerosis. Neuromuscul Disord 13 (2003) 158-161
72. Rossignol E., D'Anjou G., Lapointe N., Haddad E., and Vanasse M. Evolution and treatment of childhood chronic inflammatory polyneuropathy. Pediatr Neurol 36 (2007) 88-94
73. Sabatelli M., Madia F., Mignogna T., et al. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol 248 (2001) 772-777
74. Simmons Z., Wald J.J., and Albers J.W. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve 20 (1997) 1008-1015
75. Connolly A.M. Chronic inflammatory demyelinating polyneuropathy in childhood. Pediatr Neurol 24 (2001) 177-182
76. Ryan M.M., Grattan-Smith P.J., Procopis P.G., Morgan G., and Ouvrier R.A. Childhood chronic inflammatory demyelinating polyneuropathy: clinical course long-term outcome. Neuromuscul Disord 10 (2000) 398-406
77. Hattori N., Ichimura M., Aoki S., et al. Clinicopathological features of chronic inflammatory demyelinating polyradiculoneuropathy in childhood. J Neurol Sci 154 (1998) 66-71
78. Said G. Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord 16 (2006) 293-303
79. Dyck P.J., Lais A.C., Ohta M., et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50 (1975) 621-637
80. Korinthenberg R. Chronic inflammatory demyelinating polyradiculoneuropathy in children and their response to treatment. Neuropediatrics 30 (1999) 190-196
81. Simmons Z., Wald J.J., and Albers J.W. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve 20 (1997) 1569-1575
82. Rostasy K.M., Diepold K., Buckard J., et al. Progressive muscle weakness after high-dose steroids in two children with CIDP. Pediatr Neurol 29 (2003) 236-238
83. Lopate G., Pestronk A., and Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 62 (2005) 249-254
84. Hahn A.F., Bolton C.F., Pillay N., et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119 (1996) 1055-1066
85. Walk D., Li L.Y., Parry G.J., and Day J.W. Rapid resolution of quadriplegic CIDP by combined plasmapheresis and IVIg. Neurology 62 (2004) 155-156
86. Berger A.R., Herskovitz S., and Scelsa S. The restoration of IVIg efficacy by plasma exchange in CIDP. Neurology 45 (1995) 1628-1629
87. Fialho D., Chan Y.C., Allen D.C., Reilly M.M., and Hughes R.A. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatr 77 (2006) 544-547
88. Visudtibhan A., Chiemchanya S., and Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol 33 (2005) 368-372
89. Gono T., Matsuda M., Shimojima Y., et al. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. J Clin Neurosci 13 (2006) 683-687
90. Münch C., Anagnostou P., Meyer R., and Haas J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 256 (2007) 100-102
91. Hirst C., Raasch S., Llewelyn G., and Robertson N. Remission of chronic inflammatory demyelinating polyneuropathy after Alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatr 77 (2006) 800-802
92. Choudhary P.P., Thompson N., and Hughes R.A. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 242 (1995) 252-253
93. Vallat J.M., Hahn A.F., Léger J.M., et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 60 (2003) S23-S28
94. Pirko I., Kuntz N.L., Patterson M., et al. Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination. Neurology 60 (2003) 1697-1699